Safety and outcomes of patients receiving TAA-Ts ± nivolumab
| Patient ID . | Disease status before TAA-Ts (DS/SPD/cm2) . | Disease status at 6 wk after first TAA-Ts (DS/SPD/cm2) . | Therapy after TAA-Ts . | Outcome at last follow-up . | Survival at last follow-up . | GVHD/CRS . | Safety attributed to TAA-T cells . | IrAE . |
|---|---|---|---|---|---|---|---|---|
| Patient 1 | DS = 5/7.08 | PD (DS = 5/15.15) | None* | PD (32 d)* | Dead (6 mo) | None* | None | N/A |
| Patient 2 | DS = 4/3.5 | PMR (DS = 3/3.5) | None | PD (6 mo) | Unknown | None | None | N/A |
| Patient 3 | DS = 2/<1 | CCR DS = 2/<1 | None | CCR (42 mo) | Alive (42 mo) | None | None | N/A |
| Patient 4 | DS = 3/13.28 | CCR DS = 3 | Nivolumab +Bv started 2 mo from TAA-T | CCR (40 mo) | Alive (40 mo) | None | None | Myositis 6 mo after TAA-T |
| Patient 5 | DS = 4 | DS = 3 | Nivolumab resumed after first TAA-T | SD (20 mo) | Alive (20 mo) | None | None | Autoimmune encephalitis 6 mo after TAA-T |
| Patient 6 | DS = 5/9 | PMR (DS = 4/5.4) | Nivolumab resumed 6 wk after first TAA-T† | CR (20 mo) | Alive (20 mo) | None | None | Hypothyroidism before TAA-T |
| Patient 7 | DS = 5/23.5 | SD (DS = 5/26.3) | Nivolumab resumed 6 wk after first TAA-T | PD (6 mo) | Alive (12 mo) | Grade 1 skin autoreactivity | None | None |
| Patient 8 | DS = 5/37.9 | SD (DS = 5/50.9) | Nivolumab resumed 6 wk after first TAA-T | PD (6 mo) | Alive (15 mo) | Grade 1 CRS | None | None |
| Patient 9 | DS = 5/29.7 | SD (DS = 5/43.5) | Nivolumab resumed 6 wk after first TAA-T; ongoing | SD (12 mo) | Alive (12 mo) | None | None | Hypothyroidism before TAA-T |
| Patient 10 | DS = 5/6.57 | SD (DS = 5/6.57) | Nivolumab resumed 6 wk after first TAA-T; ongoing | SD (12 mo) | Alive (12 mo) | None | None | Hypothyroidism before TAA-T |
| Patient ID . | Disease status before TAA-Ts (DS/SPD/cm2) . | Disease status at 6 wk after first TAA-Ts (DS/SPD/cm2) . | Therapy after TAA-Ts . | Outcome at last follow-up . | Survival at last follow-up . | GVHD/CRS . | Safety attributed to TAA-T cells . | IrAE . |
|---|---|---|---|---|---|---|---|---|
| Patient 1 | DS = 5/7.08 | PD (DS = 5/15.15) | None* | PD (32 d)* | Dead (6 mo) | None* | None | N/A |
| Patient 2 | DS = 4/3.5 | PMR (DS = 3/3.5) | None | PD (6 mo) | Unknown | None | None | N/A |
| Patient 3 | DS = 2/<1 | CCR DS = 2/<1 | None | CCR (42 mo) | Alive (42 mo) | None | None | N/A |
| Patient 4 | DS = 3/13.28 | CCR DS = 3 | Nivolumab +Bv started 2 mo from TAA-T | CCR (40 mo) | Alive (40 mo) | None | None | Myositis 6 mo after TAA-T |
| Patient 5 | DS = 4 | DS = 3 | Nivolumab resumed after first TAA-T | SD (20 mo) | Alive (20 mo) | None | None | Autoimmune encephalitis 6 mo after TAA-T |
| Patient 6 | DS = 5/9 | PMR (DS = 4/5.4) | Nivolumab resumed 6 wk after first TAA-T† | CR (20 mo) | Alive (20 mo) | None | None | Hypothyroidism before TAA-T |
| Patient 7 | DS = 5/23.5 | SD (DS = 5/26.3) | Nivolumab resumed 6 wk after first TAA-T | PD (6 mo) | Alive (12 mo) | Grade 1 skin autoreactivity | None | None |
| Patient 8 | DS = 5/37.9 | SD (DS = 5/50.9) | Nivolumab resumed 6 wk after first TAA-T | PD (6 mo) | Alive (15 mo) | Grade 1 CRS | None | None |
| Patient 9 | DS = 5/29.7 | SD (DS = 5/43.5) | Nivolumab resumed 6 wk after first TAA-T; ongoing | SD (12 mo) | Alive (12 mo) | None | None | Hypothyroidism before TAA-T |
| Patient 10 | DS = 5/6.57 | SD (DS = 5/6.57) | Nivolumab resumed 6 wk after first TAA-T; ongoing | SD (12 mo) | Alive (12 mo) | None | None | Hypothyroidism before TAA-T |
Data cutoff date was 27 April 2021.
Allo-HSCT, allogeneic hematopoietic stem cell transplant; Bv brentuximab vedotin; CCR, continued complete remission; CR, complete response; CRS, cytokine release syndrome; DS, Deauville Score: SPD sum of the product of the diameters; IrAE, immune-related adverse events; PD, progressive disease; PMR, partial metabolic response; SD, stable disease; XRT, radiation; N/A, not applicable.
Patient came off study before 6-wk safety monitoring because of clinical progression, received nivolumab as standard of care per treating physician, and developed grade 4 GVHD attributed to nivolumab.
Received nivolumab for 4 cycles followed by XRT to residual mediastinal mass and went into CR and proceeded to allogeneic HSCT at 6 months from TAA-Ts.